Regeneron Pharmaceuticals (REGN) Current Assets (2009 - 2026)

Regeneron Pharmaceuticals' Current Assets history runs 18 years deep, the most recent figure standing at $18.4 billion for Q2 2026.

• In Q2 2026, Current Assets rose 9.41% year-over-year to $18.4 billion; the TTM figure through Jun 2026 stood at $18.4 billion (up 9.41% YoY), while the FY2025 annual figure was $18.0 billion, down 3.42% from the prior year.
• Current Assets for Q2 2026 stood at $18.4 billion, up from $18.2 billion in the prior quarter.
• The five-year high for Current Assets was $19.5 billion in Q4 2023, with the low at $14.3 billion in Q1 2022.
• The 5-year median for Current Assets is $18.0 billion (2025), against an average of $17.6 billion.
• The sharpest annual moves came in 2022 and 2025: Current Assets jumped 42.28% in 2022, then retreated 11.65% in 2025.
• Regeneron Pharmaceuticals' Current Assets stood at $15.9 billion in 2022, then rose by 22.63% to $19.5 billion in 2023, then decreased by 4.2% to $18.7 billion in 2024, then dropped by 3.42% to $18.0 billion in 2025, then increased by 2.35% to $18.4 billion in 2026.
• Business Quant data shows REGN's Current Assets at $18.4 billion in Q2 2026, $18.2 billion in Q1 2026, and $18.0 billion in Q4 2025.